NCT02002936已完成1 期
Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome - Extension Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Adverse Events
研究概览
简要总结
This is an extension study to investigate long term safety and efficacy of SyB C-1101 when orally administered every 3 weeks, twice daily for 14 consecutive days to the patients who have completed 6 cycles in the study 2012002 whose purpose is to investigate tolerability of SyB C-1101 when administered orally in patients with recurrent/relapsed or refractory myelodysplastic syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must satisfy the following conditions listed below.
- •Patients enrolled in the study 2012002 of SyB C-1101 in Patients With Myelodysplastic Syndrome.
- •Patients who were not judged as disease progression* nor progressive disease/relapse** at the end of the cycle 6 in the study
- •* hematologic remission according to IWG 2006 criteria ** hematologic improvement according to IWG 2006 criteria
- •Patients who met the continuation criteria*** after Cycle 6 week 3 (Day 22±3) in the study
- •***defined in the study 2012002 protocol "4.5 Criteria for Transition to the Next Cycle "
- •Patients who can be expected to survive at least three months or longer.
- •Patients who have score of 0 to 2 in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS).
- •Patients with adequate function in major organs (heart, lungs, liver, kidneys, etc.).
- •Aspartate aminotransferase (AST): no more than 3.0 times the upper boundary of the reference range at each institution
- •Alanine aminotransferase (ALT): no more than 3.0 times the upper boundary of the reference range at each institution
- •Total bilirubin: no more than 1.5 times the upper boundary of the reference range at each institution
- •Serum creatinine: no more than 1.5 times the upper boundary of the reference range at each institution
- •ECG: no abnormal findings requiring treatment
- •Echocardiography: no abnormal findings requiring treatment
- •Patients who personally signed an informed consent document for participation in this study.
排除标准
- •Patients who satisfy any of the following conditions after Cycle 6 week 3 (Day 22±3) in the study 2012002 will not be enrolled in the study.
- •Patients with anemia caused by factors other than MDS(hemolytic anemia, gastrointestinal hemorrhage, etc.).
- •Patients with obvious infectious diseases (including viral infections).
- •Patients with serious complications (liver failure, renal failure, etc.).
- •Patients with a complication of serious heart disease (myocardial infarction, ischemic heart disease, etc.)
- •Patients with a serious gastrointestinal condition (severe or significant nausea/vomiting, diarrhea, etc.)
- •Patients with serious bleeding tendencies (disseminated intravascular coagulation (DIC), internal hemorrhage, etc.).
- •Ascites or pleural fluid requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of < 130 mEq/L).
- •Patients with known allergy to polyethylene glycol or gelatin capsules.
- •Patients with an addiction to a legal or illegal drug, or with alcohol dependency.
- •Patients who are nursing, pregnant or may become pregnant, or lactating mothers.
- •Patients who have not consented to the following contraceptive measures. Patients will avoid sexual intercourse with sexual partners or should use the following contraceptive methods in these time periods: for male patients during the administration period of the trial and for six months after the end of administration; female patients during the administration period of the trial and until a second menstrual period is confirmed after the end of administration (or in the case of female patients with no menstrual period, for two months after the end of administration). 1) Male patients: Patients will always use a condom.
- •For effective contraception, it is recommended that the female partner also use the contraceptive methods for female patients. 2) Female patients: Female patients who may become pregnant should use one or more types of the following contraceptive methods. In addition, the male partner will always use a condom.
- •Oral contraceptive (birth control pills)
- •Intrauterine device (IUD)
- •Tubal ligation
- •Other patients judged to be unsuitable by an investigator or sub-investigators.
研究组 & 干预措施
SyB C-1101
Experimental
干预措施: SyB C-1101 (Drug)
结局指标
主要结局
Adverse Events
时间窗: Up to 3 years
Total number affected by any adverse events (details are presented in adverse event section)
次要结局
- Total Efficacy in Hematologic Remission (IWG2006 Criteria)(Up to 3 years)
- Cytogenetic Response Ratio According to IWG 2006 Criteria(Up to 3 years)
- Total Efficacy in Hematologic Improvement Ratio According to IWG 2006 Criteria.(Up to 3 years)
- Overall Survival(Up to 3 years)
- Changes in Clinical Laboratory Test Results(Up to 3 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension StudyMyelodysplastic SyndromeNCT02000154SymBio Pharmaceuticals1
已完成
1 期
Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)Myelodysplastic SyndromeNCT02014051SymBio Pharmaceuticals10
撤回
1 期
Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic SyndromeMyelodysplastic SyndromeNCT02783547SymBio Pharmaceuticals
已完成
1 期
Study of SyB C-1101 in Patients With Myelodysplastic SyndromeMyelodysplastic SyndromeNCT03495167SymBio Pharmaceuticals10
已完成
1 期
Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)Myelodysplastic SyndromeNCT01700335SymBio Pharmaceuticals9